Projects per year
Personal profile
Research interests
To understand how the vascular complications of diabetes develop and progress and how we can target specific pathways to delay, stop or reverse diabetic micro-and macrovascular complications including heart and kidney disease.
Biography
I am Deputy Head of the Department of Diabetes at Monash University, School of Translational Medicine and lead the research program Diabetes and Kidney disease. I am Professor of Medicine at Monash University, the University of Hannover, Germany and have an honory affiliation with Maastricht University, the Netherlands. I hold the prestigeous Leibniz Chair for Diabetes Research at the University of Dusseldorf,Germany where I also lead a Research group in diabetic nephropathy.
My research program is considered one of the leading groups in diabetic compliactions, nephropathy and cardiovascular disease in the world.
My team was the first to describe the role of NADPH oxidases in diabetic complications. This has resulted in 6 papers in nephropathy (JASN 2014; Diabetes 2017-on front cover, and Diabetologia 2017). Furthermore, the group has published 7 papers in atherosclerosis (Circulation 2013, ATVB 2016 and Diabetologia 2014) as well as in retinopathy. Overall I have published > 170 publications in the top journals of nephrology, cardiovascular research and diabetes. My h-index is 56 and I have >10,000 citations.
I am increasingly invited to write expert reviews and editorials (> 20) and am invited to present at the major meetings in diabetes, nephrology and cardiovascular research (> 40 international invitations in the last 5 years), often as plenary or keynote lecturer.
I am currently Chief investigator on 2 NHMRC project grants and in my role as a clinician/scientist lead a clinical trial on a novel Nox inhibitor in diabetic kidney disease in type 1 diabetes. Inded, I have secrured a multimillion dollar grant from JDRF and ARC for this investigator initiated trial which is currently recruiting at 15 sites in Australia, NZ, Denmark and in Germany.
I have established many international high level collaborations (Prof R Touyz, Glasgow University, Prof H Schmidt, University of Maastricht, and Prof C Godson, University of Dublin.
I am a past president of the Australian Athersclerosis Society and serve on editorial boards for several journal: Diabetologia> 8 years, Clinical Science, PlosOne, Journal Molecular Medicine and the Australian RACP endorsed Internal Mediccine Journal.
Furthermore, I am co-chair of the BmedSc program at CCS, Monash University and have supervised > 20 Honours students and 5 PhD students to completion.
Currently we work on several programs on the role of Nox5 in diabetic complications, the role of epigenetic mechanisms in diabetic complications specifically atherosclerosis and on inflammasome inhibition in diabetic kidney disease.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Diabetes
- Diabetic complications
- diabetic nephropathy
- cardiovascular disease
- oxidative stress
- reactive oxygen species
- unstable plaque
- novel targets
- clinical translation
Collaborations and top research areas from the last five years
-
Translational Kidney Fibrosis Imaging in Diabetes
Alt, K. (Primary Chief Investigator (PCI)), Jandeleit-Dahm, K. (Chief Investigator (CI)) & Jha, J. (Chief Investigator (CI))
1/01/24 → 31/07/25
Project: Research
-
Innovative screening and treatment approaches for diabetic complications
Jandeleit-Dahm, K. (Primary Chief Investigator (PCI))
1/01/23 → 31/12/27
Project: Research
-
NOX5 is a novel target in diabetic kidney disease
Jandeleit-Dahm, K. (Primary Chief Investigator (PCI))
15/03/22 → 14/03/23
Project: Research
-
Point of care detection of early kidney disease using infrared spectroscopy
Jandeleit-Dahm, K. (Primary Chief Investigator (PCI)), Shaw, J. (Chief Investigator (CI)), Brown, A. D. H. (Chief Investigator (CI)) & Ekinci, E. (Chief Investigator (CI))
1/01/22 → 31/12/22
Project: Research
-
NOX5 in circulating peripheral blood mononuclear cells as a new biomarkerfor unstable diabetic cardiovascular disease
Block, T. (Primary Chief Investigator (PCI)), Jandeleit-Dahm, K. (Chief Investigator (CI)), Shaw, J. (Chief Investigator (CI)) & Cooper, M. (Chief Investigator (CI))
1/01/22 → 31/12/22
Project: Research
-
Does the expression of glucagon-like peptide-1 receptor on bone marrow derived cells influence the onset and progression of diabetic kidney disease?
Sourris, K. C., Bertuzzo Veiga, C., Kantharidis, P., Rosado, C., Bose, M., Dimitropoulos, A., Xu, Y., Coughlan, M. T., Aziz, M., Morgan, P., Drucker, D. J., Murphy, A. J., Jandeleit-Dahm, K. A. M. & Cooper, M. E., Sept 2024, In: Diabetologia. 67, S1, p. S106 1 p., OP198.Research output: Contribution to journal › Meeting Abstract › peer-review
Open AccessFile -
Endothelial NOX5 Obliterates the Reno-Protective Effect of Nox4 Deletion by Promoting Renal Fibrosis via Activation of EMT and ROS-Sensitive Pathways in Diabetes
Jandeleit-Dahm, K. A. M., Kankanamalage, H. R., Dai, A., Meister, J., Lopez-Trevino, S., Cooper, M. E., Touyz, R. M., Kennedy, C. R. J. & Jha, J. C., Apr 2024, In: Antioxidants. 13, 4, 18 p., 396.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Citations (Scopus) -
Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products–induced inflammation
Sourris, K. C., Ding, Y., Maxwell, S. S., Al-Sharea, A., Kantharidis, P., Mohan, M., Rosado, C., Penfold, S., Haase, C. G., Xu, Y., Forbes, J. M., Crawford, S. A., Ramm, G., Harcourt, B. E., Jandeleit-Dahm, K. A. M., Advani, A., Murphy, A. J., Timmermann, D. B., Karihaloo, A. & Knudsen, L. B. & 4 others, , Jan 2024, In: Kidney International. 105, 1, p. 132-149 18 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access54 Citations (Scopus) -
Elucidating NOX5 as a Potential Therapeutic Target and a Biomarker of Kidney Disease in Diabetes FR-PO376
Jha, J., Kankanamalage, H. R., Jaquet, V., Cooper, M. E. & Jandeleit-Dahm, K. A. M., Nov 2023, In: Journal of the American Society of Nephrology. 34, 11S, p. 507 1 p.Research output: Contribution to journal › Meeting Abstract › peer-review
-
Nox5: a promising therapeutic target for diabetic kidney disease
Jha, J. C., Dai, A., Kankanamalage, H. R., Meister, J., Vincent, J., Cooper, M. E. & Jandeleit-Dahm, K., Sept 2023, In: Diabetologia. 66, Suppl 1, p. S71 1 p., 132.Research output: Contribution to journal › Meeting Abstract › peer-review
Prizes
-
Fellow of the Australian Academy of Health and Medical Sciences (AAHMS)
Jandeleit-Dahm, K. (Recipient), Oct 2018
Prize: National/international honour
-
Hans Christian Hagedorn Award
Jandeleit-Dahm, K. (Recipient), 2022
Prize: National/international honour
-
Leibniz Chair, German Diabetes Centre and Leibniz Centre for Diabetes Research at the Heinrich Heine University, Dusseldorf, Germany
Jandeleit-Dahm, K. (Recipient), Dec 2019
Prize: National/international honour